N@N

SANTARUS INC (NASDAQ:SNTS), Down By 6.31% ($0.31) From $4.899 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bear

^{Published on 2012-02-17 07:40:56 - WOPRAI}
 

February 17, 2012 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Thursday, February 2nd 2012 stating that SANTARUS INC (NASDAQ:SNTS) was expected to go Down due to the Bearish conditions presented in the following report. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=snts&id=238905

At the time this story was written, SANTARUS INC (NASDAQ:SNTS) is Down By $0.31 (6.31%) since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following specific fundamental or technical events may follow a predictable pattern. Many companies stock price histories show random or unpredictable movements around certain events. But some seem to repeat the same pattern quarter after quarter, year after year. We use powerful computers to uncover those events and correlations to generate predictions with high probabilities of generating very specific returns within very specific time periods.

The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

SANTARUS INC (NASDAQ:SNTS) - Santarus, Inc., a specialty biopharmaceutical company, engages in acquiring, developing, and commercializing proprietary products that address the needs of patients treated by physician specialists. The company commercializes CYCLOSET (bromocriptine mesylate) tablets, and focuses to commercialize GLUMETZA (metformin hydrochloride extended release tablets) that are indicated as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes. It also has a development pipeline with three late-stage product candidates in Phase III clinical programs, including ULTESA (budesonide MMX) for induction of remission of active ulcerative colitis, rifamycin SV MMX for treatment of travelers diarrhea, and RHUCIN (recombinant human C1 inhibitor) for the treatment of acute attacks of hereditary angioedema. In addition, Santarus plans to initiate a Phase I clinical study for SAN-300, an anti-VLA-1 antibody development compound that it expects to develop for the treatment of rheumatoid arthritis. The company was founded in 1996 and is based in San Diego, California.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor market-maker surveillance system tracking Level II market-makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 30 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies specifically for this report, but may have been compensated up to $1,200 per month in the past for unrelated data or report services. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net